Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review-Reference-Cited by-同舟云学术

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review

Published:2008-04 Issue:2 Volume:34 Page:157-174
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Eisen Andrea,Trudeau Maureen,Shelley Wendy,Messersmith Hans,Pritchard Kathleen I.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference80 articles.

1. Eisen A, Pritchard KI, Johnston M, Oliver T, and the Breast Cancer Disease Site Group. The role of aromatase inhibitors in the treatment of post-menopausal women with metastatic breast cancer [summary] [monograph on the Internet]. Cancer Care Ontario Practice Guidelines Initiative. 2003 [cited 2003 Jul 11]. .

2. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints;Parmar;Stat Med,1998

3. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen vs. tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9.

4. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.

5. BIG 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Search for New Inhibitors of Human Aromatase Enzyme (Cyp450) from Bioactive Compounds of Citrus species;Oriental Journal Of Chemistry;2023-10-30

2. Description of Chemical Synthesis, Nuclear Magnetic Resonance Characterization and Biological Activity of Estrane-Based Inhibitors/Activators of Steroidogenesis;Molecules;2023-04-15

3. Radiotherapy in Breast Cancer;Interdisciplinary Cancer Research;2023

4. Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance;Cancer Drug Resistance;2022

5. Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience;Journal of Bone Oncology;2021-12